These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 10813716)

  • 1. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
    Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
    Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
    Hoff PM; Valero V; Buzdar AU; Singletary SE; Theriault RL; Booser D; Asmar L; Frye D; McNeese MD; Hortobagyi GN
    Cancer; 2000 May; 88(9):2054-60. PubMed ID: 10813717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raloxifene in breast cancer prevention.
    Gennari L; Merlotti D; Paola VD; Nuti R
    Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiestrogen therapy in the treatment of breast neoplasms].
    Alba E; Ragonesi G; Colla F; Mazzoleni A; Farina C
    Minerva Ginecol; 2002 Jun; 54(3):245-51. PubMed ID: 12063440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of breast cancer.
    Thomsen A; Kolesar JM
    Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
    Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
    Vogel VG
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene rebound regression.
    Dosik M; Kaufman R
    Cancer Invest; 2004; 22(5):718-22. PubMed ID: 15581053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
    Martínez Marín V; Muñoz Martín AJ; Viñuela Benéitez MC; García Alfonso P; Alonso Muñoz A; Pérez Manga G
    Med Clin (Barc); 2009 Sep; 133(10):371-4. PubMed ID: 19339025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.